Mainz Biomed B.V. (MYNZ)

Business: Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics.

IPO Date: 05-Nov-2021

CEO & Director: Mr. Guido Baechler

Chief Financial Officer: Mr. William J. Caragol

Listing: NASDAQ: MYNZ

Country: Germany

Headquarters: Mainz,

Website: https://mainzbiomed.com

Market cap: $141.70 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-11.69 Mln

Cash: $8.73 Mln

Total Debt: $0.00 Mln

Insider's Holding: 24.69%

Liquidity: Low

52 Week range: $5.00 - 30.00

Shares outstanding: 13,960,500